KDR and non-small cell lung carcinoma: In the phase 1 JVDF trial, a combination of the anti‐VEGFR‐2 antibody, ramucirumab, plus the anti‐PD‐1 antibody pembrolizumab led to an ORR of 42.3%, including patients previously treated for NSCLC.31